Open a new chapter in intelligent healthcare | FANGZHOU JIANKE (06086) joins hands with Bayer to promote industry innovation and development.

On December 16th, FANGZHOU JIANKE (06086) and Bristol-Myers Squibb Company (BMY.US) held a signing ceremony for their strategic cooperation agreement in Shanghai, China. Dr. Xie Fangmin, the founder, chairman, and CEO of FANGZHOU JIANKE, signed the agreement with the head of the China Innovation Drug Division and General Manager of the Hong Kong market of Bristol-Myers Squibb Company, Wen Yizhong. The two parties will deepen their cooperation on aspects such as building a digital medical platform and upgrading internet health management models to explore new paths for innovation in internet medical services. In recent years, many industries have witnessed a wave of digital transformation, with the "Internet + Healthcare" model attracting attention from both the industry and capital markets. How to leverage technological advantages to promote comprehensive industry upgrades? How to deliver quality services and innovative drugs to millions of households? The cooperation between FANGZHOU JIANKE and Bristol-Myers Squibb Company has provided a bright answer to these questions. The comprehensive upgrade of "technology + services" is an inevitable choice for enterprise development under the wave of digital transformation. Dr. Xie Fangmin stated, "FANGZHOU JIANKE has strong technological capabilities, and Bristol-Myers Squibb Company has a solid research and development foundation. With strategic cooperation as a new starting point, the powerful alliance between the two parties will bring a new benchmark for health management models and inject new vitality into the internet medical and health field." "We have a deep foundation for cooperation with FANGZHOU JIANKE, and we have witnessed FANGZHOU JIANKE's solid progress in the internet medical field and the improvement of its technology and services." Wen Yizhong said that by leveraging FANGZHOU JIANKE's strong technological foundation and artificial intelligence research advantages, the collaboration between the two parties will generate sustainable empowering effects, achieving a synergistic effect greater than the sum of its parts, and driving the overall innovation and development of the industry. It is understood that this strategic cooperation will focus on in-depth collaboration around the treatment drug Liboloz for beta-thalassemia and the psoriasis treatment drug Song Di Duo, exploring innovative digital marketing project management models. It is worth mentioning that Liboloz recently successfully renewed its inclusion in the national medical insurance catalog, and its new indications applied for this year are expected to be approved by 2025; Song Di Duo has also been officially included in the national medical insurance catalog this year, and starting from 2025, the burden of disease for relevant patients is expected to be further reduced. Illuminate the future of health with technology! The strategic cooperation between FANGZHOU JIANKE and Bristol-Myers Squibb Company is not only a deep exploration and reshaping of the internet medical and health management model but also a vibrant practice in safeguarding the health of the people. Looking ahead, FANGZHOU JIANKE will join hands with Bristol-Myers Squibb Company to drive the transformation of both parties' strengths in digital innovation, comprehensive channel cooperation, and chronic disease management services, forming a strong synergy to help build a healthy future for China's internet medical industry.